Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases
Shots:
- The agreement leverages Imbio's technical- regulatory & commercial expertise to build medical imaging AI technology for use in research- clinical trials & clinical practice
- The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio's expertise in imaging biomarkers with Genentech's pulmonary disease expertise for enhancing drug development and delivering more personalized healthcare
- Imbio will continue to develop & market its portfolio of quantitative imaging algorithms for lung & cardiothoracic diseases apart from the collaboration
Ref: PR Newswire | Image: UT Health
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com